This study focuses on Juvenile Psoriatic Arthritis, a condition that causes joint inflammation in children and is often accompanied by a skin condition called psoriasis. The research examines the effectiveness of a medication called Apremilast, which will be compared to placebo in children aged 5 to less than 18 years old. The purpose of this study is to determine if Apremilast can help treat the symptoms of Juvenile Psoriatic Arthritis in young patients.
During the study, participants will receive either Apremilast (known as AMG 407) or placebo in the form of tablets or oral solution. The medication or placebo will be taken by mouth. The treatment period will last for 52 weeks, with the main assessment of the medication’s effectiveness occurring at week 16.
The study will monitor several aspects of the disease, including joint pain, inflammation, and overall disease activity. For participants who also have psoriasis affecting their skin, the improvement in skin symptoms will also be evaluated. The medication will be provided in different strengths, including 10 mg, 20 mg, and 30 mg tablets, as well as a liquid form containing 5 mg/mL.
Austria 
Belgium 
France 
Germany 
Greece 
Italy 
Lithuania 
Poland 
Portugal 
Romania 
Spain 
The Netherlands